HIV/AIDS Topics HIV Prevention CROI 2014: Long-acting GSK744 Protects Monkeys against HIV-like Virus [VIDEO]
CROI 2014: Long-acting GSK744 Protects Monkeys against HIV-like Virus [VIDEO]
- Details
- Category: HIV Prevention
- Published on Wednesday, 05 March 2014 00:00
- Written by Liz Highleyman
A long-acting injectable formulation of the next-generation integrase inhibitor GSK1265744 protected monkeys from infection via vaginal or anal exposure to a hybrid human-simian virus, according to 2 studies presented at the 21st Conference on Retroviruses and Opportunistic Infections (CROI 2014) this week in Boston. These promising findings suggest this may be a future approach to pre-exposure prophylaxis (PrEP).
[Chasity Andrews and J. Gerardo Garcia-Lerma,CROI press conference, March 4, 2014]
3/5/14
Sources
CD Andrews, W Spreen, YL Yueh, et al. Correlating GSK1265744 Plasma Levels To Prevention of Rectal SHIV Transmission in Macaques. 21st Conference on Retroviruses and Opportunistic Infections (CROI 2014). Boston, March 3-6. Abstract 39.
J Radzio, W Spreen, YL Yueh, JG Garcia-Lerma, et al. Monthly GSK744 Long-Acting Injections Protect Macaques Against Repeated Vaginal SHIV Exposures. 21st Conference on Retroviruses and Opportunistic Infections (CROI 2014). Boston, March 3-6. Abstract 40LB.
Press conference. 21st Conference on Retroviruses and Opportunistic Infections (CROI 2014). Boston. March 4, 2014.
Web Design and Development by